文献速递炎症性肠病肝病

炎症性肠病患者两剂Heplisav-B疫苗接种后无免疫者第三剂Heplisav-B效用的研究

Utility of a Third Heplisav-B Dose in Patients With Inflammatory Bowel Disease Without Immunity After 2-Dose Heplisav-B Vaccination.
PubMed 文献 · Am J Gastroenterol · 2024-05-08

本研究前瞻性评估炎症性肠病(IBD)患者在两剂Heplisav-B疫苗接种后未产生乙肝免疫者接受第三剂疫苗的效果。192例患者中71.9%(138/192)在两剂后血清学转换,54例未转换者中30例接受第三剂,56.7%(17/30)实现血清学转换(中位HBsAb滴度376 IU/L,IQR 47-1,000 IU/L),中位接种间隔416天(IQR 90.8-667.8)。作者认为第三剂Heplisav-B可能是两剂接种后无免疫患者的有效策略。

要点

  • IBD患者两剂Heplisav-B后71.9%(138/192)血清学转换,28.1%(54/192)未转换。
  • 54例未转换者中30例(55.6%)接受第三剂,56.7%(17/30)实现血清学转换。
  • 第三剂后血清学转换者中位HBsAb滴度376 IU/L(IQR 47-1,000 IU/L)。

核心结论

  • 在IBD患者中,两剂Heplisav-B接种后无乙肝免疫者接受第三剂后血清学转换率为56.7%。
  • 作者认为,对初次两剂接种后仍无免疫的患者,追加一剂Heplisav-B可能是有效策略。

研究设计与样本

  • 前瞻性评估2018年至2023年间接受两剂Heplisav-B疫苗接种的成人IBD患者。
  • 血清学转换定义为接种后≥4周测得的乙肝表面抗体(HBsAb)≥10 IU/L。
  • 未血清学转换者前瞻性接受第三剂Heplisav-B并复查HBsAb。
  • 比较血清学转换与未转换者的人口学、临床、用药和疫苗接种数据。

主要发现

  • 192例患者中,两剂Heplisav-B后71.9%(138/192)血清学转换。
  • 未血清学转换的54例(28.1%)更可能为男性、患糖尿病、慢性肾病或Charlson合并症指数升高。
  • 54例中30例(55.6%)选择接受第三剂,其中56.7%(17/30)实现血清学转换,中位HBsAb滴度376 IU/L(IQR 47-1,000 IU/L)。
  • 第三剂接种的中位间隔时间为416天(IQR 90.8-667.8)。
  • 第三剂接种后血清学转换者与未转换者之间未见差异。

关键数值与推荐

  • 血清学转换定义为接种后≥4周HBsAb≥10 IU/L。
  • 两剂Heplisav-B后血清学转换率为71.9%(138/192)。
  • 第三剂Heplisav-B后血清学转换率为56.7%(17/30),中位HBsAb滴度376 IU/L(IQR 47-1,000 IU/L)。

临床怎么用

  • 作者认为,对两剂Heplisav-B接种后仍无乙肝免疫的IBD患者,追加一剂Heplisav-B可能是有效策略。
  • 原文未据此给出其他临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Hepatitis B virus (HBV) vaccination is recommended in patients with inflammatory bowel disease (IBD). Although the 2-dose Heplisav-B vaccine has proven effective, more than 20% of patients with IBD do not seroconvert. We prospectively evaluated the effectiveness of a third Heplisav-B dose in patients with IBD lacking HBV immunity despite 2-dose vaccination. METHODS: Adults with IBD who had received 2-dose Heplisav-B vaccination between 2018 and 2023 were identified. Seroconversion was defined as hepatitis B surface antibody (HBsAb) ≥ 10 IU/L measured at ≥4 weeks after vaccination. Patients who did not seroconvert were prospectively offered a third Heplisav-B dose, followed by repeat HBsAb measurement. Demographic, clinical, medication, and vaccination data were compared between those who did and did not seroconvert. RESULTS: Of 192 patients identified, 71.9% (138/192) seroconverted after 2-dose Heplisav-B vaccination. The 54 patients (28.1%) who did not seroconvert were more likely to be male, have diabetes, chronic kidney disease, or elevated Charlson Comorbidity Index. Of the 54 patients, 30 (55.6%) elected to receive a third Heplisav-B dose, with 56.7% (17/30) achieving seroconversion (median HBsAb titer 376 IU/L, IQR 47-1,000 IU/L) despite a median intervaccination time of 416 days (IQR 90.8-667.8). No differences were noted between patients who did vs did not seroconvert after third-dose vaccination. DISCUSSION: In patients with IBD lacking HBV immunity despite 2-dose Heplisav-B vaccination, administration of a third dose resulted in a 56.7% seroconversion rate. Our results suggest that administration of an additional Heplisav-B dose may be an effective strategy in patients lacking immunity despite primary 2-dose vaccination.

来源:Am J Gastroenterol,查看原文。版权归原作者所有。

引用

  1. Karime C, Black CN, Cortes P, et al. Utility of a Third Heplisav-B Dose in Patients With Inflammatory Bowel Disease Without Immunity After 2-Dose Heplisav-B Vaccination. Am J Gastroenterol. 2024. PMID: 38717045. doi:10.14309/ajg.0000000000002863

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。